ANIX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 20:20):

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases...

Stats
Šios dienos apimtis	33 131.00
Vidutinė apimtis	122 936
Rinkos kapitalizacija	95.71M
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $-0.0900 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.82
ATR14	$0.0140 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Catelani Michael	Buy	1 189	Common Stock
2024-04-09	Titterton Lewis H Jr	Buy	15 009	Common Stock
2024-03-15	Baskies Arnold M	Buy	10 000	Common Stock
2024-03-15	Kumar Amit	Buy	30 000	Common Stock
2024-01-12	Baskies Arnold M	Buy	25 000	Employee Stock Option (Right to Buy)

INSIDER POWER
61.22
Last 100 transactions
Buy: 11 627 548 \| Sell: 3 491 117

Tūris Koreliacija

Ilgas: 0.18 (neutral)

Trumpas: 0.44 (neutral)

Signal:(37.027) Neutral

Anixa Biosciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TCON	0.862
AFMD	0.862
TECH	0.859
UTMD	0.856
TOUR	0.855
CDMO	0.855
HSIC	0.854
XRAY	0.854
ATXI	0.851
INFI	0.851

10 Labiausiai neigiamai susiję koreliacijos
TYHT	-0.869
NUVL	-0.866
TLND	-0.853
JUPW	-0.852
NAAC	-0.851
HERA	-0.851
HERAU	-0.85
SVFA	-0.85
CPAQ	-0.85
VPCB	-0.848

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Anixa Biosciences Inc Koreliacija - Valiuta/Žaliavos

0.26
( neutral )

0.09
( neutral )

0.67
( moderate )

0.16
( neutral )

-0.67
( moderate negative )

-0.41
( neutral )

Anixa Biosciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$210 000
Bruto pelnas:	$49 000.00 (23.33 %)
EPS:	$-0.320

FY	2023
Pajamos:	$210 000
Bruto pelnas:	$49 000.00 (23.33 %)
EPS:	$-0.320

FY	2022
Pajamos:	$2.47B
Bruto pelnas:	$2.47B (100.00 %)
EPS:	$-0.440

FY	2021
Pajamos:	$512 500
Bruto pelnas:	$127 498 (24.88 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.